Roche Holding


Competition intensifies in already crowded multiple sclerosis space

05/09/19 -"Novartis’ Arzerra is all set to enter the fast-growing/crowded MS space (likely in 2020) banking on superior clinical data vs. Sanofi’s Aubagio. While this would dent the sales of Aubagio, Novartis’ ..."

Pages
63
Language
English
Published on
05/09/19
You may also be interested by these reports :
21/01/20
Lonza reported a mixed set of condensed 2019 figures, which were below our expectations (EBITDA: -5%) but broadly met consensus based on adjusted ...

20/01/20
We have become a tad more confident on Bayer as we expect the businesses to come in a bit stronger than expected. We also have a feeling that the ...

13/01/20
Given the strong uptake of Cimzia (33% of sales) and Vimpat (25% of sales) across geographies in Q4 19, we have upgraded our revenue estimates for ...

23/12/19
The Democratic version of the pharmaceutical pricing bill has managed to get through one of the houses in the US. With the ruling party also in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO